Head of Alliance Management

• Oct 2021 - Present

Responsible for managing 10 partnerships for 18 in-licensed assets in neurology, psychiatry, and ophthalmology for AffaMed Therapeutics (the parent company), AffaMed Technologies (a Joint Venture), and AffaMed Digital (the Digital Therapeutics subsidiary). Established the Alliance Management function and instituted alliance best practices.

Senior Director, Alliance Management

• May 2021 - Sep 2021

Director, Global Alliance Management

• Aug 2016 - May 2021

- Manage Research, Development, and Commercial stage alliances for multiple therapeutic indications with large pharmaceutical, small biotechnology companies, and academic partners.- Manage the entire alliance life cycle to maximize alliance value and minimize risks.

Senior Principal Scientist, Neuroimmunology Research

• Oct 2011 - Jul 2016

• External Innovation and Alliance Management: Led the scientific evaluation of and decision making for external opportunities for disease modifying and symptomatic therapies for Multiple Sclerosis. Participated in negotiations of contracts, and served as Global Project Lead and Alliance Manager for short-term, early-stage agreements. • Internal discovery research and product support: Oversaw cell-based assay development to model neuroprotection and neural repair (remyelination) for target validation, candidate therapeutic assessments, and mechanism of action studies. Senior group member contributing to strategy and priorities for the Neuroimmunology group. Show less

Principal Scientist, Oncology Research

• Apr 2009 - Sep 2011

Participated in the evaluations of external opportunities for oncology. Led internal focus groups tasked with creating and reviewing new target proposals. Led efforts to validate expression and function of early-stage targets. Provided support for Campath as scientific representative to Global Product Team and by overseeing efforts to better understand the biology of the CD52 protein target.

Senior Scientist, Oncology Research

• May 2003 - Mar 2009

Participated in the evaluation of external opportunities for oncology. Led target validation work for cell surface proteins for oncology and Immune-Mediated Diseases. Developed and utilized angiogenic cell-based assays to test candidate therapeutics.

Staff Scientist Level II, Gene Expression and Analysis Group

• Jul 2000 - May 2003

Established collaboration with an academic investigator and served as project leader identifying differentially expressed genes in normal and transformed prostate cells from a transgenic mouse model utilizing serial analysis of gene expression (SAGE), microarray, real-time PCR, and bioinformatics.

Staff Scientist Level I and Head of Positional Cloning Group

• Jun 1997 - Jun 2000

Responsible for internal efforts to clone the Human Prostate Cancer Tumor Suppressor Gene HPC1 with multiple collaborators.